These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35381683)

  • 1. [Durable molecular remission in a patient with relapsed NPM1/IDH1 mutant acute myeloid leukemia treated with venetoclax combined with azacitidine: a case report].
    Liu XH; Wu Y; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):166. PubMed ID: 35381683
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.
    Pollyea DA; DiNardo CD; Arellano ML; Pigneux A; Fiedler W; Konopleva M; Rizzieri DA; Smith BD; Shinagawa A; Lemoli RM; Dail M; Duan Y; Chyla B; Potluri J; Miller CL; Kantarjian HM
    Clin Cancer Res; 2022 Jul; 28(13):2753-2761. PubMed ID: 35046058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and
    Wang L; Song J; Xiao X; Li D; Liu T; He X
    J Chemother; 2024 May; 36(3):202-207. PubMed ID: 37599456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
    Zappasodi P; Brociner M; Merati G; Nizzoli ME; Roncoroni E; Boveri E; Castagnola C; Arcaini L
    Ann Hematol; 2021 Apr; 100(4):1111-1113. PubMed ID: 33175198
    [No Abstract]   [Full Text] [Related]  

  • 5. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
    Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
    [No Abstract]   [Full Text] [Related]  

  • 6. [Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].
    Zong LH; Wu XX; Zhang J; Li MY; Song BQ; Kong JY; Kong X; Hu XH; Bao XB; Qiu HY; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):861-864. PubMed ID: 34788928
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax.
    Niswander LM; Chung P; Diorio C; Tasian SK
    Haematologica; 2023 Nov; 108(11):3142-3147. PubMed ID: 37021525
    [No Abstract]   [Full Text] [Related]  

  • 8. [Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].
    Tian FQ; Zhang LS; Li JH; Tang MQ; Jiang J; Cheng XH; Zhang XC; Jiang M
    Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):694-696. PubMed ID: 32942828
    [No Abstract]   [Full Text] [Related]  

  • 9. Ex vivo drug sensitivity profiling-guided treatment of a relapsed pediatric mixed-phenotype acute leukemia with venetoclax and azacitidine.
    Gonzales F; Guilmatre A; Barthélémy A; Lapillonne H; Pottier N; Leverger G; Petit A; Cheok MH
    Pediatr Blood Cancer; 2022 Oct; 69(10):e29678. PubMed ID: 35353439
    [No Abstract]   [Full Text] [Related]  

  • 10. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
    Pratz KW; DiNardo CD; Selleslag D; Li J; Yamamoto K; Konopleva M; Stevens D; Kantarjian H; Traina F; Venditti A; Mayer J; Montez M; Jin H; Duan Y; Brackman D; Zha J; Potluri J; Werner M; Jonas BA
    Am J Hematol; 2022 Nov; 97(11):E416-E419. PubMed ID: 36054316
    [No Abstract]   [Full Text] [Related]  

  • 11. Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.
    Bouligny IM; Murray G; Ho T; Doyel M; Patel T; Boron J; Tran V; Gor J; Hang Y; Alnimer Y; Zacholski K; Venn C; Wages NA; Grant S; Maher KR
    Leuk Res; 2023 Nov; 134():107370. PubMed ID: 37659346
    [No Abstract]   [Full Text] [Related]  

  • 12. Myeloid sarcoma of the urinary bladder as the presenting feature of secondary acute myeloid leukemia, successfully treated with venetoclax and azacitidine.
    Lucijanic M; Tomasovic-Loncaric C; Stoos-Veic T; De Both T; Jalsenjak B; Kusec R
    Ann Hematol; 2024 Feb; 103(2):671-672. PubMed ID: 37946030
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.
    Lou Y; Shao L; Mao L; Lu Y; Ma Y; Fan C; Jiang H; Li J; Jin J
    Leuk Res; 2020 Apr; 91():106317. PubMed ID: 32092584
    [No Abstract]   [Full Text] [Related]  

  • 15. Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?
    Niscola P; Gianfelici V; Giovannini M; Piccioni D; Mazzone C; Fabritiis P
    Ann Hematol; 2024 May; 103(5):1787-1788. PubMed ID: 38459155
    [No Abstract]   [Full Text] [Related]  

  • 16. Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukaemia in routine clinical practice.
    Liu Y; Zhu L; Lv Z; Mao L; Hu C; Wang J; Zhou Y; Jin J; Meng H; You L
    Br J Haematol; 2023 Jun; 201(5):995-999. PubMed ID: 36999439
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical analysis of the combination regimen with Bcl-2 inhibitor venetoclax in the treatment of 30 cases of acute myeloid leukemia with IDH1/2 mutation].
    Wang X; Bao XB; Zhang J; Song BQ; Li MY; Xie JD; Shen HJ; Wu DP; Qiu HY
    Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):691-694. PubMed ID: 36709157
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.
    Bewersdorf JP; Shimony S; Shallis RM; Liu Y; Berton G; Schaefer EJ; Zeidan AM; Goldberg A; Stein E; Marcucci G; Bystrom RP; Lindsley RC; Chen EC; Ramos J; Stein A; Pullarkat V; Aldoss I; DeAngelo DJ; Neuberg DS; Stone RM; Garciaz S; Ball B; Stahl M
    Am J Hematol; 2024 Aug; 99(8):1640-1643. PubMed ID: 38751104
    [No Abstract]   [Full Text] [Related]  

  • 19. [Efficacy of venetoclax combined azacitidine in newly diagnosed acute myeloid leukemia unfit for standard chemotherapy: a single center experience].
    Sun L; Ye SJ; Zhou N; Han XZ; Qi JX; Liu XJ; Luo JM; Yang L
    Zhonghua Xue Ye Xue Za Zhi; 2022 Oct; 43(10):826-832. PubMed ID: 36709196
    [No Abstract]   [Full Text] [Related]  

  • 20. Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
    Zhao P; Ni M; Ma D; Fang Q; Zhang Y; Li Y; Huang Y; Chen Y; Chai X; Zhan Y; Li Y; Kang Q; Zhao M; Liu M; Zhang F; Huang S; Wen S; Deng B; Wang J
    Ann Hematol; 2022 Jan; 101(1):119-130. PubMed ID: 34568973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.